Spotlight on glycopyrronium/formoterol fumarate inhalation aerosol in the management of COPD: design, development, and place in therapy

References

• WHOProjections of mortality and causes of death, 2015–2030WHO2014 Available from: http://www.who.int/healthinfo/global_burden_disease/projections/enaccessed April 17, 2017
   Google Scholar
• MathersCDLoncarDProjections of global mortality and burden of disease from 2002 to 2030PLoS Med2015311e442
   Web of Science ®Google Scholar
• Global Initiative for Obstructive Lung DiseaseGlobal strategy for the diagnosis, management and prevention of chronic obstructive pulmonary diseaseGOLD2017 Available from: http://www.goldcopd.org2017Accessed April 17, 2017
   Google Scholar
• MagnussenHDisseBRodriguez-RoisinRWithdrawal of inhaled glucocorticoids and exacerbations of COPDN Engl J Med2014371141285129425196117
   PubMed Web of Science ®Google Scholar
• AppletonSPoolePSmithBJLong-acting beta2-agonists for poorly reversible chronic obstructive pulmonary diseaseCochrane Database of Systematic Reviews20063CD001104
   Google Scholar
• Schultze-WerninghausGMulticenter 1-year trial on formoterol, a new long-acting β2-agonist, in chronic obstructive airway diseaseLung1990168183891974687
   PubMed Web of Science ®Google Scholar
• MaesenFPSmeetsJJGubbelmansHLLZweersPGBronchodilator effect of inhaled formoterol versus salbutamol over 12 hoursChest19909735905941968371
   PubMed Web of Science ®Google Scholar
• DahlRGreefhorstLANowakDInhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2001164577878411549532
   PubMed Web of Science ®Google Scholar
• FusoLIncalziRABassoSEffects of formoterol inhaled dry powder on exercise performance in chronic obstructive pulmonary disease: a single-center, randomized, double-blind, placebo-controlled, crossover studyCurr Ther Res Clin Exp200364531732624944380
   PubMed Web of Science ®Google Scholar
• AalbersRAyresJBackerVFormoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trialEur Respir J200219593694312030736
   PubMed Web of Science ®Google Scholar
• CampbellMElirazAJohanssonGFormoterol for maintenance and as-needed treatment of chronic obstructive pulmonary diseaseRespir Med200599121511152016199148
   PubMed Web of Science ®Google Scholar
• QuinnDSealeJPReisnerCA randomized study of formoterol fumarate in a porous particle metered-dose inhaler in patients with moderate-to-severe COPDRespir Med201410891327133525060541
   PubMed Web of Science ®Google Scholar
• SlovisCMDanielsGMWhartonDRIntravenous use of glycopyrrolate in acute respiratory distress due to bronchospastic pulmonary diseaseAnn Emerg Med19871688989003619169
   PubMed Web of Science ®Google Scholar
• CydulkaRKEmermanCLEffects of combined treatment with glycopyrrolate and albuterol in acute exacerbation of chronic obstructive pulmonary diseaseAnn Emerg Med1995254470473 Available from: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=cctr&NEWS=N&AN=CN-00112786Accessed April 17, 2017.7710150
   PubMed Web of Science ®Google Scholar
• FogartyCHattersleyHDiLDrollmannABronchodilatory effects of NVA237, a once daily long-acting muscarinic antagonist, in COPD patientsRespir Med2011105333734221144724
   PubMed Web of Science ®Google Scholar
• LaForceCFeldmanGSpangenthalSEfficacy and safety of twice-daily glycopyrrolate in patients with stable, symptomatic COPD with moderate-to-severe airflow limitation: the GEMI studyInt J COPD201611112331243
   Google Scholar
• D’UrzoAFergusonGTvan NoordJAEfficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trialRespir Res201112115622151296
   PubMed Web of Science ®Google Scholar
• KerwinEHébertJGallagherNEfficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 studyEur Respir J20124051106111423060624
   PubMed Web of Science ®Google Scholar
• WangCSunTHuangYEffcacy and safety of once-daily glycopyrronium in predominantly Chinese patients with moderate-to-severe chronic obstructive pulmonary disease: the GLOW7 studyInt J COPD2015105768
   Google Scholar
• BeehKMSinghDDi ScalaLDrollmannAOnce-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trialInt J COPD20127503513
   Google Scholar
• ChapmanKRBeehKBeierJA blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 studyBMC Pulm Med201414111124387157
   PubMed Web of Science ®Google Scholar
• FrithPAThompsonPJRatnavadivelRGlycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study, a randomised controlled trialThorax201570651952725841237
   PubMed Web of Science ®Google Scholar
• RennardSFogartyCReisnerCRandomized study of the safety, pharmacokinetics, and bronchodilatory efficacy of a proprietary glycopyrronium metered-dose inhaler in study patients with chronic obstructive pulmonary diseaseBMC Pulm Med201414111825027304
   PubMed Web of Science ®Google Scholar
• KewKMSeniukovichAInhaled steroids and risk of pneumonia for chronic obstructive pulmonary diseaseCochrane Database Syst Rev2014103CD010115
   Google Scholar
• KunzLIZPostmaDSKloosterKRelapse in FEV1 Decline After Steroid Withdrawal in COPDChest2015148238939625836351
   PubMed Web of Science ®Google Scholar
• SinghDWorsleySZhuCHardakerLChurchAUmeclidinium/vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trialBMC Pulm Med2015159126286141
   PubMed Web of Science ®Google Scholar
• FarneHACatesCJLong-acting beta 2-agonist in addition to tiotropium versus either tiotropium or long-acting beta 2-agonist alone for chronic obstructive pulmonary diseaseCochrane Database Syst Rev20151010CD008989
   Google Scholar
• MartinezFJRabeKFFergusonGTEfficacy and safety of glycopyrrolate/formoterol MDI formulated using Co-Suspension™ Delivery Technology in patients with COPDChest2016151201734035727916620
   PubMed Web of Science ®Google Scholar
• HananiaNATashkinDPKerwinESafety and efficacy of a novel LAMA/LABA co-suspension technology Glycopyrrolate/Formoterol fixed-dose combination delivered by MDI: results of a one-year extension study in patients with COPD (PINNACLE-3)D36. COPD: LABA, LAMA, ICS, and combinations. American Thoracic Society International Conference AbstractsAmerican Thoracic Society2016A6791A6791
   Google Scholar
• HanrahanJPGroganDRBaumgartnerRAArrhythmias in patients with chronic obstructive pulmonary disease (COPD)Medicine (Baltimore)200887631932819011503
   PubMed Web of Science ®Google Scholar
• CampbellSCCrinerGJLevineBECardiac safety of formoterol 12 microg twice daily in patients with chronic obstructive pulmonary diseasePulm Pharmacol Ther200720557157916911869
   PubMed Web of Science ®Google Scholar
• WiseRAAnzuetoACottonDTiotropium Respimat inhaler and the risk of death in COPDN Engl J Med2013369161491150123992515
   PubMed Web of Science ®Google Scholar
• Van de MaeleBFabbriLMMartinCHortonRDolkerMOverendTCardiovascular safety of QVA149, a combination of Indacaterol and NVA237, in COPD patientsCOPD20107641842721166630
   PubMedGoogle Scholar
• VogelmeierCVerkindreCCheungDSafety and tolerability of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patientsPulm Pharmacol Ther201023543844420416390
   PubMed Web of Science ®Google Scholar